Barbara Tate, PhD

Barbara Tate, PhD, is The Chief Scientific Officer of FARA, Previously, she was the Chief of Strategy and a venture partner at the Dementia Discovery Fund (DDF), SV Life Sciences. She has worked in both large and small pharmaceutical companies, where she has held executive positions. She was a founder and the first CEO of Tiaki Therapeutics, a DDF portfolio company. She was also a founder of and the Vice President and Head of Biology at Rodin Therapeutics, an Atlas Venture company, where she also consulted on other portfolio companies. Prior to Rodin, Barbara was Vice President for Research at Satori Pharmaceuticals, a biotech company developing a treatment for Alzheimer’s disease. At Pfizer, Barbara managed the neurodegenerative disease area group in Groton, CT. Prior to working in industry, Barbara was an academic researcher at Brown Medical School and Harvard Medical School. Barbara has a BA in Biology from Beaver College, a PhD in Physiology for the University of Delaware, and completed a postdoctoral fellow at Harvard Medical School.